Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug

This publication has 26 references indexed in Scilit:

• Can a Class III Antiarrhythmic Drug Improve Electrical Defibrillation Efficacy During Ventricular Fibrillation?
  Journal of the American College of Cardiology, 1997
• Myocardial Potassium Channels: Electrophysiological and Molecular Diversity
  Annual Review of Physiology, 1996
• Inhibition of ATP‐Sensitive Potassium Channels in Cardiac Myocytes by the Novel Class III Antiarrhythmic Agent MS‐551
  Basic & Clinical Pharmacology & Toxicology, 1995
• Cellular electrophysiological effects of MS‐551, a new class III antiarrhythmic agent
  Drug Development Research, 1995
• 901–41 Preliminary Mortality Results from the Survival with Oral D-Sotalol (SWORD) Trial
  Journal of the American College of Cardiology, 1995
• MS-551 Protects Against Ventricular Fibrillation in a Chronic Canine Model of Sudden Cardiac Death
  Journal of Cardiovascular Pharmacology, 1995
• Effects of the New Class III Antiarrhythmic Drug MS-551 and d-Sotalol on Canine Coronary Ligation-Reperfusion Ventricular Arrhythmias
  The Japanese Journal of Pharmacology, 1995
• Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction Model
  Journal of Cardiovascular Pharmacology, 1994
• Selective block of delayed rectifying potassium current in the rabbit sinoatrial node by a novel class III antiarrhythmic agent MS-551
  Heart and Vessels, 1994
• Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction
  New England Journal of Medicine, 1989